Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

With Chinese firms becoming major players in drug development, the traditional balance of power in global pharmaceuticals is ...

With profit at an eight-year high, pharmaceutical May & Baker Nigeria Plc reported a 56 percent growth despite high operation ...

Gilead Sciences, Inc. GILD reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025.

Water is the hidden ingredient in many products and production processes, but it is taking an increasingly central role as ...

Its UK #NationalApprenticeshipWeek, so we've put together a list of our top ten manufacturing apprenticeship schemes led by ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Royalty Pharma to provide R&D investment of up to $250 million for Biogen’s litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupusNEW YORK, Feb. 12, 2025 ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...

Over the last few years, this under-the-radar technology business has quietly become one of the largest companies in the FTSE ...

The most recent news from Nigeria and across the world is available at The News Chronicle. The News Chronicle provides the ...